相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A rare Ebola strain has infected over 1,100 people and killed more than 300 in Congo and Uganda, with no available vaccine or treatment. - France confirmed its first imported case after a humanitarian doctor fell ill on a commercial flight from Kinshasa, prompting Congo to impose a 21-day quarantine for international travelers. - Atlanta's Emory Healthcare, which successfully treated two Ebola patients in 2014, maintains a biocontainment unit and collaborates with the CDC, Grady Memorial Hospital, and state health authorities. - Dr. Gavin Harris of Emory Healthcare cautioned that respiratory viruses like measles, chicken pox, and flu pose a greater threat to World Cup crowds than Ebola, which requires close bodily contact for transmission.
- AI model quantifies breast arterial calcifications on routine mammograms, correlating severity with up to eightfold increased cardiovascular event risk. - DeepHealth receives FDA clearance for automated BAC detection, enabling opportunistic heart disease screening without additional radiation, time, or cost. - Severe BAC levels linked to fourfold to eightfold increases in heart attack and stroke; BAC under age 50 signals elevated 10-year cardiovascular risk. - Over 40 million annual U.S. mammograms could become dual-purpose screening tools for both breast cancer and heart disease, the leading cause of death among women.
- Motif Neurotech received FDA approval for the RESONATE early feasibility study to test its XCS System, a wirelessly-powered brain implant for treatment-resistant depression. - The blueberry-sized device delivers electrical stimulation to brain regions without direct brain contact, activated by wearing a baseball hat-like external component. - The trial will evaluate safety and efficacy in patients who have not responded to two or more medications across eight leading medical institutions. - Nearly 3 million Americans live with treatment-resistant depression, representing a significant unmet medical need for this novel brain-computer interface approach.
- Microbot Medical has commenced full market release of its LIBERTY Endovascular Robotic System at the Society of Interventional Radiology conference after successful limited market adoption by multiple healthcare systems including Emory Healthcare and Tampa General Hospital. - The LIBERTY system represents the only FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures, demonstrating versatility across multiple procedure types including prostate artery embolization and uterine fibroid embolization. - The company has expanded its commercial infrastructure from four to eight sales territories with plans to reach 12 territories by end of 2026, while recent peer-reviewed publication in the Journal of Vascular and Interventional Radiology validates the system's clinical efficacy.
- Steroid response rates in chronic graft-vs-host disease remain at approximately 50%, prompting research into combination therapies and earlier introduction of newer drugs to improve treatment outcomes. - Biomarker-guided therapy represents a revolutionary approach that could replace current generalized treatment algorithms with personalized care protocols for chronic GVHD patients. - Clinicians are increasingly using off-label combination therapies, such as combining Rexona and belimumab, to achieve steroid-sparing regimens and reduce long-term toxicity risks. - The development of steroid-free first-line treatments is a critical research priority to eliminate cardiovascular complications, osteoporosis, and diabetes associated with long-term steroid use.
- A novel radiogenomics approach uses machine learning to predict the risk of pneumonitis in stage III non-small cell lung cancer (NSCLC) patients before treatment. - The study identifies key radiomic features from CT scans that correlate with gene expression profiles, potentially revealing molecular mechanisms linked to pneumonitis development. - A predictive model combining clinical features and radiomic signatures demonstrates improved risk assessment for pneumonitis compared to clinical factors alone. - The discriminative model accurately distinguishes between radiation-induced and immunotherapy-induced pneumonitis, aiding in tailored treatment strategies.
